DGX — Quest Diagnostics Share Price
- $14.31bn
- $18.58bn
- $9.25bn
- 86
- 60
- 68
- 82
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 14.53 | ||
PEG Ratio (f) | 1.6 | ||
EPS Growth (f) | 10.01% | ||
Dividend Yield (f) | 2.26% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.27 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 16.57 | ||
Price to Sales | 1.55 | ||
EV to EBITDA | 10.92 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 10.34% | ||
Return on Equity | 13.93% | ||
Operating Margin | 13.64% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 7,726 | 9,437 | 10,788 | 9,883 | 9,252 | 9,400.61 | 9,730.93 | 4.2% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +12.95 | +68.77 | +44.61 | -47.03 | -8.15 | +10.79 | +7.6 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.
Directors
- Stephen Rusckowski CHM (64)
- James Davis CEO (59)
- Mark Guinan CFO (60)
- Michael Prevoznik SVP (59)
- Catherine Doherty SVP (58)
- Carrie Manner SVP (46)
- Timothy Ring LED (64)
- Tracey Doi IND
- Vicky Gregg IND (66)
- Wright Lassiter IND (57)
- Timothy Main IND (63)
- Denise Morrison IND (67)
- Gary Pfeiffer IND (71)
- Helen Torley IND (58)
- Gail Wilensky IND (77)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 20th, 1996
- Public Since
- December 17th, 1996
- No. of Shareholders
- 2,110
- No. of Employees
- 40,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 110,707,293
- Address
- 500 Plaza Drive, SECAUCUS, 07094
- Web
- https://www.questdiagnostics.com/
- Phone
- +1 9735202700
- Contact
- Shawn Bevec
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for DGX
Dividend For DGX.N - 0.7500 USD
Q1 2024 Quest Diagnostics Inc Earnings Call
Q1 2024 Quest Diagnostics Inc Earnings Release
Quest Diagnostics Inc Annual Shareholders Meeting
Q2 2024 Quest Diagnostics Inc Earnings Release
Similar to DGX
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
Auna SAA
New York Stock Exchange
FAQ
As of Today at 18:17 UTC, shares in Quest Diagnostics are trading at $129.30. This share price information is delayed by 15 minutes.
Shares in Quest Diagnostics last closed at $129.30 and the price had moved by -4.5% over the past 365 days. In terms of relative price strength the Quest Diagnostics share price has underperformed the S&P500 Index by -27.55% over the past year.
The overall consensus recommendation for Quest Diagnostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Quest Diagnostics dividend yield is 2.16% based on the trailing twelve month period.
Last year, Quest Diagnostics paid a total dividend of $2.79, and it currently has a trailing dividend yield of 2.16%.Looking ahead, shares in Quest Diagnostics are due to go ex-dividend on 2024-04-05 and the next dividend pay date is 2024-04-22.
Quest Diagnostics are due to go ex-dividend on 2024-04-05 and the next dividend pay date is 2024-04-22. The historic dividend yield on Quest Diagnostics shares is currently 2.16%.
To buy shares in Quest Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $129.30, shares in Quest Diagnostics had a market capitalisation of $14.31bn.
Here are the trading details for Quest Diagnostics:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: DGX
Based on an overall assessment of its quality, value and momentum Quest Diagnostics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Quest Diagnostics is $141.71. That is 9.6% above the last closing price of $129.30.
Analysts covering Quest Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of $8.75 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quest Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -13.23%.
As of the last closing price of $129.30, shares in Quest Diagnostics were trading -2.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quest Diagnostics PE ratio based on its reported earnings over the past 12 months is 14.53. The shares last closed at $129.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quest Diagnostics' management team is headed by:
- Stephen Rusckowski - CHM
- James Davis - CEO
- Mark Guinan - CFO
- Michael Prevoznik - SVP
- Catherine Doherty - SVP
- Carrie Manner - SVP
- Timothy Ring - LED
- Tracey Doi - IND
- Vicky Gregg - IND
- Wright Lassiter - IND
- Timothy Main - IND
- Denise Morrison - IND
- Gary Pfeiffer - IND
- Helen Torley - IND
- Gail Wilensky - IND